Clinical Trials Sponsored by Stellah Mpagama

Total 1397 results

Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation. (SENIOR)

Kidney Transplantation

Belgium, France, Germany, Spain, Switzerland, United Kingdom, Netherlands
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Irritable Bowel Syndrome

Poland, Germany, Bulgaria, Ukraine, Estonia, Russian Federation, Czech Republic, Lithuania
Astellas Pharma Europe B.V.

Completed

Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

United Kingdom
Astellas Pharma China, Inc.

Completed

Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis

Moderate/Severe Atopic Dermatitis

China
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Effect of Race

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Japanese | Caucasian

Germany
Astellas Pharma Inc
Astellas Pharma US, Inc.

Terminated

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Melanoma

United States
Astellas Pharma Inc
Astellas Pharma US, Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

Kidney Transplantation

United States
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Prostate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate

Netherlands, United States, United Kingdom
Astellas Pharma Europe B.V.

Completed

Drug to Drug Interaction Study With Ipragliflozin and Furosemide

Healthy Subjects | Pharmacokinetics of Ipragliflozin

United Kingdom
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients

Overactive Bladder | Urinary Bladder, Overactive

Korea, Republic of
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate

Rheumatoid Arthritis

Korea, Republic of
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) (VECTOR)

Overactive Bladder

Canada
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Terminated

Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward

Schizophrenia

Taiwan
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

Optimizing Prograf® Therapy in Renal Transplant Patients (OPTIMA)

Renal Transplantation

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients

Kidney Transplantation

Korea, Republic of
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Asthma, Bronchial | Bronchial Asthma

Russian Federation, Poland, Germany, Ukraine, Czech Republic
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Asthma, Bronchial | Bronchial Asthma

Russian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
Astellas Pharma Korea, Inc.

Not yet recruiting

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Europe Ltd.

Completed

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients (CHORUS)

Kidney Transplantation

Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Thailand, United Kingdom, Vietna...
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Astellas Pharma China, Inc.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

Healthy Volunteers

China
Astellas Pharma China, Inc.

Completed

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

China
Astellas Pharma Korea, Inc.

Completed

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Astellas Pharma Europe Ltd.

Completed

Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis

Chronic Kidney Disease (CKD)

Sweden
Astellas Pharma Korea, Inc.

Terminated

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Type 2 Diabetes Mellitus

Korea, Republic of
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Kidney Transplantation

Canada
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee (OAK)

Osteoarthritis of the Knee | Chronic Lower Back Pain

Belgium, Czechia, Germany, Hungary, Spain, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Endometriosis

Belgium, Bulgaria, Germany, Hungary, Japan, Poland, Romania, Ukraine, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Astellas Pharma China, Inc.

Terminated

A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

Kidney Transplant Recipients

China
Astellas Pharma China, Inc.

Completed

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

Kidney Transplant Recipients

China
Astellas Pharma China, Inc.

Terminated

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

Candidemia | Candidiasis

China
Astellas Pharma China, Inc.

Terminated

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

Invasive Aspergillosis

China
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM)

Type 2 Diabetes | Chronic Kidney Disease

Spain, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Korea, Inc.

Completed

Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation

Kidney Transplantation

Korea, Republic of
Astellas Pharma Europe Ltd.

Completed

A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment (ELEVATE)

Non-diabetic Painful Peripheral Polyneuropathy | Postherpetic Neuralgia (PHN) | Peripheral Nerve Injury (PNI)

Armenia, Austria, Belarus, Belgium, Bulgaria, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Turkey, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Europe B.V.

Completed

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (MOBILE)

Neuropathic Pain | Post-Herpetic Neuralgia (PHN) | Painful Diabetic Peripheral Neuropathy (PDPN)

Czechia, Germany, Poland, United Kingdom
Astellas Pharma Europe B.V.

Terminated

A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy (BiGARD)

NSAID-induced Gastropathy

Russian Federation
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Heart Diseases | Heart Transplantation

Canada, United States
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)

Renal Transplantation | Chronic Renal Allograft Failure

Canada
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP6294

United Kingdom

3

Subscribe